- Title
- 73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis
- Creators
- E. Yu - University of WashingtonJ.M. Piulats - Institut Català d'OrnitologiaG. Gravis - Institut Paoli-CalmettesP. Fong - Auckland City HospitalT. Todenhöfer - Clinical Trial Unit, Studienpraxis Urologie, Nürtingen, GermanyB. Laguerre - Centre Eugène MarquisJ. Arranz - Hospital General Universitario Gregorio MarañónS. Oudard - Hôpital Européen Georges-PompidouC. Massard - Institut Gustave RoussyM. Stoeckle - Universitätsklinikum des SaarlandesL.T. Nordquist - Urology Cancer Center and GU Research NetworkJ. Carles - Vall d'Hebron Institute of OncologyM. Huang - Merck & Co., Inc., Rahway, NJ, USA (United States)Y. Li - Merck & Co., Inc., Rahway, NJ, USA (United States)P. Qiu - Merck & Co., Inc., Rahway, NJ, USA (United States)C.H. Poehlein - Merck & Co., Inc., Rahway, NJ, USA (United States)C. Schloss - Merck & Co., Inc., Rahway, NJ, USA (United States)J. de Bono - Institute of Cancer Research
- Publication Details
- Annals of oncology, Vol.32, pp.S387-S387
- Publisher
- Elsevier Ltd
- Identifiers
- 991006262298702656
- Academic Unit
- Radiology
- Language
- English
- Resource Type
- Journal article
Journal article
73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis
Annals of oncology, Vol.32, pp.S387-S387
09/2021
Metrics
1 Record Views